Dechra offers complete answer to canine osteoarthritis cases
The launch of this diet complements the company’s analgesic and anti-inflammatory products, Pardale® and Flexicam®, and means that Dechra can offer veterinarians a complete solution to the management of canine osteoarthritis cases in practice.
Osteoarthritis is one of the most common clinical conditions seen in dogs today, with orthopaedic experts suggesting that at least one third of the European canine population may be affected. Its aetiology is complex with genetic, lifestyle and nutritional factors each playing their part.
Although pharmaceutical products are indicated for the control of pain, particularly in the acute phases of the disease process, nutritional management is now recognised as a significant clinical tool for both the prevention and alleviation of canine osteoarthritis.
SPECIFIC™ CJD Joint Support offers the following features and benefits:
- Highest level of EPA* = enhanced anti-inflammatory action and reduced cartilage degradation
- Highest level of GAGs* = enhanced joint protection
- Moderate energy level* = enhanced maintenance of an optimal weight
- Veterinary exclusive = enhanced partnership
SPECIFIC™ CJD Joint Support is available in ‘freshness’ packaging for optimal efficacy and preservation of the product’s high levels of Ω-3 fatty acids and is available in 2.5 kg, 6.5 kg and 13 kg bags (2 x 6.5 kg).
Country
